BIOCYTOGEN-B (02315) Surges Over 5% Intraday After Successful STAR Market Listing, Establishing Dual A+H Listing Platform

Stock News2025-12-12

BIOCYTOGEN-B (02315) rose more than 5% during intraday trading, settling at a 4.15% gain to HK$28.12 by press time, with a turnover of HK$19.51 million. The company made its debut on the Shanghai Stock Exchange's STAR Market on December 10. This marks a significant milestone following its initial listing on the Hong Kong Stock Exchange on September 1, 2022, solidifying its "H+A" dual-listing structure and enhancing capital market positioning.

Western Securities highlighted in a research report that BIOCYTOGEN-B launched its "Thousand Mice Ten Thousand Antibodies" program in March 2020, adopting an "antibody library" model. This approach not only reduces R&D timelines and early-stage uncertainties but also enables parallel evaluation of multiple targets, potentially boosting pharmaceutical partners' R&D efficiency and clinical success rates.

The company's antibody business, initiated in 2020, generated annual revenue of RMB41 million that year. By the first half of 2025, revenue surged to RMB163 million, reflecting a 37.8% YoY increase. With further clinical advancements of pipeline molecules, the platform's value is expected to expand further.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128280146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-12 15:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128280146","market":"sg","top_or_hot":-1,"title":"BIOCYTOGEN-B (02315) Surges Over 5% Intraday After Successful STAR Market Listing, Establishing Dual A+H Listing Platform","media":"Stock News","content":"<p>BIOCYTOGEN-B (02315) rose more than 5% during intraday trading, settling at a 4.15% gain to HK$28.12 by press time, with a turnover of HK$19.51 million. The company made its debut on the Shanghai Stock Exchange's STAR Market on December 10. This marks a significant milestone following its initial listing on the Hong Kong Stock Exchange on September 1, 2022, solidifying its \"H+A\" dual-listing structure and enhancing capital market positioning.</p>\n<p>Western Securities highlighted in a research report that BIOCYTOGEN-B launched its \"Thousand Mice Ten Thousand Antibodies\" program in March 2020, adopting an \"antibody library\" model. This approach not only reduces R&D timelines and early-stage uncertainties but also enables parallel evaluation of multiple targets, potentially boosting pharmaceutical partners' R&D efficiency and clinical success rates.</p>\n<p>The company's antibody business, initiated in 2020, generated annual revenue of RMB41 million that year. By the first half of 2025, revenue surged to RMB163 million, reflecting a 37.8% YoY increase. With further clinical advancements of pipeline molecules, the platform's value is expected to expand further.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BIOCYTOGEN-B (02315) Surges Over 5% Intraday After Successful STAR Market Listing, Establishing Dual A+H Listing Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBIOCYTOGEN-B (02315) Surges Over 5% Intraday After Successful STAR Market Listing, Establishing Dual A+H Listing Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-12 15:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BIOCYTOGEN-B (02315) rose more than 5% during intraday trading, settling at a 4.15% gain to HK$28.12 by press time, with a turnover of HK$19.51 million. The company made its debut on the Shanghai Stock Exchange's STAR Market on December 10. This marks a significant milestone following its initial listing on the Hong Kong Stock Exchange on September 1, 2022, solidifying its \"H+A\" dual-listing structure and enhancing capital market positioning.</p>\n<p>Western Securities highlighted in a research report that BIOCYTOGEN-B launched its \"Thousand Mice Ten Thousand Antibodies\" program in March 2020, adopting an \"antibody library\" model. This approach not only reduces R&D timelines and early-stage uncertainties but also enables parallel evaluation of multiple targets, potentially boosting pharmaceutical partners' R&D efficiency and clinical success rates.</p>\n<p>The company's antibody business, initiated in 2020, generated annual revenue of RMB41 million that year. By the first half of 2025, revenue surged to RMB163 million, reflecting a 37.8% YoY increase. With further clinical advancements of pipeline molecules, the platform's value is expected to expand further.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1128280146","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128280146","pubTimestamp":1765525618,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BIOCYTOGEN-B (02315) rose more than 5% during intraday trading, settling at a 4.15% gain to HK$28.12 by press time, with a turnover of HK$19.51 million. The company made its debut on the Shanghai...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159982":"中证500","688796":"百奥赛图","BK1161":"生物科技","02315":"百奥赛图-B"},"translate_title":"生物奥赛图-B(02315)科创板成功上市后盘中大涨超5%，建立A+H双上市平台","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159982":1,"688796":1,"02315":1},"content_text":"BIOCYTOGEN-B (02315) rose more than 5% during intraday trading, settling at a 4.15% gain to HK$28.12 by press time, with a turnover of HK$19.51 million. The company made its debut on the Shanghai Stock Exchange's STAR Market on December 10. This marks a significant milestone following its initial listing on the Hong Kong Stock Exchange on September 1, 2022, solidifying its \"H+A\" dual-listing structure and enhancing capital market positioning.\nWestern Securities highlighted in a research report that BIOCYTOGEN-B launched its \"Thousand Mice Ten Thousand Antibodies\" program in March 2020, adopting an \"antibody library\" model. This approach not only reduces R&D timelines and early-stage uncertainties but also enables parallel evaluation of multiple targets, potentially boosting pharmaceutical partners' R&D efficiency and clinical success rates.\nThe company's antibody business, initiated in 2020, generated annual revenue of RMB41 million that year. By the first half of 2025, revenue surged to RMB163 million, reflecting a 37.8% YoY increase. With further clinical advancements of pipeline molecules, the platform's value is expected to expand further.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128280146","isCrawlerRequest":true}